The World Health Organisation’s International Agency for Research in Cancer (WHO-IARC) has now declared hepatitis D, a little-known but deadly virus, carcinogenic, with the hope that it will lead to ...

LA Times Studios produces content by working closely with scientists and healthcare experts as well as sourcing scholarly-reviewed medical and science journals and does not involve the Los Angeles ...

Hepatitis D Virus (HDV) Particle. Image Made According To A View Under Transmission Electron Microscope, Viral Diameter 35 Nm. This is the first part of a series on hepatitis D virus, a virusoid-like ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner. Back in November, Vir arrived ...

Whether hepatitis resolves depends on the type and whether a person receives treatment. Hepatitis A usually resolves without medications, and while sometimes hepatitis B and C may last only a few ...

Despite growing awareness, many people still hold misconceptions about how hepatitis is transmitted and its effects. These ...

The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) have officially classified the Hepatitis D virus (HDV) as carcinogenic to humans. This places HDV ...

A recent study published in Alimentary Pharmacology and Therapeutics reports that patients with a lower hepatitis B virus (HBV) haplotype number of less than or equal to two are more likely to achieve ...

It's unusual for presidents to give medical advice. But this week, President Trump told parents to delay giving their kids a ...

In a press conference this week, President Trump said there's no reason to give babies the Hepatitis B vaccine. But pediatricians and infectious disease experts say this guidance is dangerous.

World Hepatitis Day 2025 and its theme, “Hepatitis: Let’s Break It Down,” emphasize the urgent need to remove barriers to prevention, testing, and treatment to reduce liver cancer and eliminate ...

Lawrence Blatt, Ph.D., CEO of Aligos Therapeutics, knows a thing or two about the slow drip of progress that has defined treating viral liver infections. He was “thrilled” back in the mid-90s when a ...